drugset / Trial / NCT07011186

A Clinical Trial of TQB3909 Tablets in Combination With Azacitidine for the Treatment of Myeloid Malignancies

NCT07011186

Phase 1/2 Recruiting 138 enrolled Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This is an open, multi-center clinical study designed to evaluate the safety, tolerability and efficacy of TQB3909 tablets in combination with azacitidine in subjects with myeloid malignancies.

Timeline

Start
2024-04-17
Primary completion
2025-10
Completion
2026-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Azacitidine Other / unclassified
Subject TQB3909 Unknown

Indications